Table 4 Summary of the most frequent all grade and grade 3/4 adverse events.

From: Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting

AE, n (%)

All grades

Grade 3–4

Neutropenia

26 (74.3)

16 (45.7)

Asthenia

23 (65.7)

6 (17.1)

Anaemia

17 (54.8)

2 (5.7)

Thrombocytopenia

12 (34.3)

2 (5.7)

Diarrhoea

12 (34.3)

2 (5.7)

Hepatic function abnormalities

8 (22.9)

0

Nausea/vomiting

6 (17.1)

3 (8.6)

Bleeding

4 (11.4)

0

Hypertension

2 (5.7)

1 (2.9)

Venous thromboembolism

0

0

Febrile neutropenia

0

0

  1. AE adverse event.